IBT International Biotechnology Ord
13.83USD1050.00 GBp · LSE+0.48%Mkt Cap: 437.66M USDP/E: 2.231d ago
Industry Peers
Capital MarketsInstitutional holders1 on file
Key Statistics
Company
Market Cap437.66M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.54M USD
Revenue/Share—
Last Price13.83 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryGB
SectorFinancial Services
IndustryCapital Markets
ISINGB0004559349
Valuation
P/E (Trailing)2.23
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.06
EPS (TTM)—
EPS (Forward)—
52W Range
11.0953% of range16.26
52W High16.26 USD
52W Low11.09 USD
Profitability
Gross Margin—
Oper. Margin—
EBITDA Margin—
Profit Margin668.57%
ROE-0.47%
ROA-0.41%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF37.71M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity0.12
Current Ratio—
Quick Ratio—
Book Value/Sh13.02 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.31.65M
Float—
Insiders—
Institutions—
Technical
SMA 5014.07 (-1.7%)
SMA 20013.42 (+3.0%)
Beta—
S&P 52W Chg—
Avg Vol (30d)60.95K
Avg Vol (10d)70.89K
Technical Indicators
RSI (14)48.3
MACD0.5113
MACD Signal1.0913
MACD Hist.-0.5800
BB Upper14.55 USD
BB Middle13.85 USD
BB Lower13.14 USD
BB Width10.20%
ATR (14)0.5214 USD
Vol Ratio (20d)0.18x
About International Biotechnology Ord (LON: IBT)
›
International Biotechnology Ord (LON: IBT) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Capital Markets industry, part of the Financial Services sector.
The shares were at 1050.00 GBp on 19 November 2026, up 15.7% over 52 weeks. Its 52-week range is 842.00 GBp to 1235.00 GBp: the price is 15.0% below the high and 24.7% above the low.
At a market capitalisation of 332.35M GBP, it trades at 2.2 times trailing earnings. The median trailing P/E of its 19 largest Capital Markets peers is 15.5, a discount of 86% for IBT.
International Biotechnology Ord reports return on equity of -0.5%.
Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.